Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 5, 2005 - Issue 4
Submit an article Journal homepage
80
Views
13
CrossRef citations to date
0
Altmetric
Drug Evaluation

A review of tositumomab and I131 tositumomab radioimmunotherapy for the treatment of follicular lymphoma

Andrew J Davies Cancer Research UK Medical Oncology Unit, Barts and The Royal London School of Medicine and Dentistry, Charterhouse Square, London, EC1M 6BQ, UK. [email protected]
Pages 577-588 | Published online: 22 Apr 2005

Bibliography

  • THE NON-HODGKIN'S LYMPHOMA CLASSIFICATION PROJECT: A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood (1997) 89:3909–3918.
  • HORNING SJ: Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin. Oncol. (1993) 20:75–88.
  • GALLAGHER CJ, GREGORY WM, JONES AE et al: Follicular lymphoma: prognostic factors for response and survival. J. Clin. Oncol (1986) 4:1470–1480.
  • JOHNSON PW, ROHATINER AZ, WHELAN J et al: Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J. Clin. Oncol (1995) 13:140–147.
  • MACMANUS MP, HOPPE RT: Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J. Clin. Oncol (1996) 14:1282–1290.
  • BRICE P, BASTION Y, LEPAGE E et al.:Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. Clin. Oncol. (1997) 15:1110–1117.
  • ARDESHNA KM, SMITH P, NORTON A et al.: Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet (2003) 362:516–522.
  • ADVANI R, ROSENBERG SA, HORNING SJ: Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy. J. Clin. Oncol (2004) 22:1454–1459.
  • HORNING SJ: Follicular lymphoma: have we made any progress? Ann. Oncol (2000) 11 (Suppl. 1):23–27.
  • CABANILLAS F, HORNING S, KAMINSKI M, CHAMPLIN R: Managing indolent lymphomas in relapse: working our way through a plethora of options. Hematol (Am. Soc. Hematol Educ. Program) (2000):166–179.
  • SOLAL-CELIGNY P, ROY P, COLOMBAT P et al.: Follicular lymphoma international prognostic index. Blood (2004) 104:1258–1265.
  • DAVE SS, WRIGHT G, TAN B et al.: Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl. J. Med. (2004) 351:2159–2169.
  • STASHENKO P, NADLER LM, HARDY R, SCHLOSSMAN SF: Characterization of a human B lymphocyte-specific antigen. J. Immunol (1980) 125:1678–1685.
  • EINFELD DA, BROWN JP, VALENTINE MA, CLARK EA, LEDBETTER JA: Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J. (1988) 7:711–717.
  • TEDDER TF, STREULI M, SCHLOSSMAN SF, SAITO H: Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. Proc. Natl Acad. Sci. USA (1988) 85:208–212.
  • BUBIEN JK, ZHOU LJ, BELL PD, FRIZZELL RA, TEDDER TF: Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J. Cell Biol. (1993) 121:1121–1132.
  • LI H, AYER LM, LYTTON J, DEANS JP: Store-operated cation entry mediated by CD20 in membrane rafts. J. Biol. Chem. (2003) 278:42427–42434.
  • ANDERSON KC, BATES MP, SLAUGHENHOUPT BL, PINKUS GS, SCHLOSSMAN SF, NADLER LM: Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood (1984) 63:1424–1433.
  • MCLAUGHLIN P, GRILLO-LOPEZ AJ, LINK BK et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol (1998) 16:2825–2833.
  • HIDDEMANN W, DREYLING MH, FORSTPOINTNER R et al.: Combined immuno-chemotherapy (R-CHOP) significantly improves time to treatment failure in first line therapy of follicular lymphoma results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Blood (2003) 102:104a (abstract).
  • FORSTPOINTNER R, DREYLING M, REPP R et al.: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood (2004) 104:3064–3071.
  • MARCUS R, IMRIE K, BELCH A et al.:CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood (2004) 105(4):1417–1423.
  • TEDDER TF, FORSGREN A, BOYD AW, NADLER LM, SCHLOSSMAN SF: Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes. Eur. J. Immunol (1986) 16:881–887.
  • BUCHSBAUM DJ, WAHL RL, NORMOLLE DP, KAMINSKI MS: Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts. Cancer Res. (1992) 52:6476–6481.
  • SHAN D, LEDBETTER JA, PRESS OW:Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood (1998) 91: 1644-1652.
  • CRAGG MS, GLENNIE MJ: Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood (2004) 103:2738–2743.
  • SHAN D, LEDBETTER JA, PRESS OW:Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother. (2000) 48:673–683.
  • DAVIS TA, KAMINSKI MS, LEONARD JP et al.: The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin. Cancer Res. (2004) 10:7792–7798.
  • •Randomised trial of unlabelled tositumomab versus tositumomab and 1131 tositumomab.
  • FRAKER PJ, SPECK JC JR: Protein andcell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem. Biophys. Res. Commun. (1978) 80:849–857.
  • O'DONOGHUE J, BARDIES M, WHELDON T: Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J. Nucl. Med. (1995) 36:1902–1909.
  • KASSIS A, ADELSTEIN S: Considerationsin the selection of Radionuclides for cancer therapy. In: Handbook of Radiopharmaceuticals: Radiochemistry and Applications. Welch M, Redvanly C (Eds), John Wiley Publishers, West Sussex, UK (2003):767–793.
  • GLAXOSMITHKLINE: GlaxoSmithKline Announces Expanded Indication for Bexxar in Non-Hodgkin's Lymphoma. (2005) Press Release.
  • KAMINSKI MS, ZASADNY KR, FRANCIS IR et al.: Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl. J. Med. (1993) 329:459–465.
  • BUCHSBAUM DJ, WAHL RI,, GLENN SD, NORMOLLE DP, KAMINSKI MS: Improved delivery of radiolabeled anti-B1 monoclonal antibody to Raji lymphoma xenografts by predosing with unlabeled anti-B1 monoclonal antibody. Cancer Res. (1992) 52:637–642.
  • KAMINSKI MS, ZASADNY KR, FRANCIS IR et al.: Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. Clin. Oncol. (1996) 14:1974–1981.
  • MONES J, COLEMAN M, KOSTAKOGLU Let al.: A dose-escalation study of tositumomab and iodine I 131 tositumomab (Bexxar) in pts with previously treated non-Hodgkin's lymphoma (NHL) with 25% bone marrow involvement. Proc. Am. Soc. Clin. Oncol (2004) 23:574 (abstract).
  • SIEGEL JA: Revised Nuclear Regulatory Commission regulations for release of patients administered radioactive materials: outpatient iodine-131 anti-Bl therapy. Nud Med. (1998) 39:28S–33S.
  • WAHL RL: The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine 1131 tositumomab. Semin. Oncol (2003) 30:31–38.
  • GOLDSMITH SJ, KAMINSKI M, WAHL RL et al.: Dosimetry optimizes radiolabelled antibody dosing in patients with non-Hodgkin's lymphoma. Proc. Am. Soc. Clin. Oncol (2001) 19:1140 (abstract).
  • KAMINSKI MS, ESTES J, ZASADNY KR et al.: Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood (2000) 96:1259–1266.
  • ••Complete data and long-term follow-up ofthe Phase I/II study from a single centre.
  • WAHL RL: Iodine-131 anti-Bl antibody therapy in non-Hodgkin's lymphoma: dosimetry and clinical implications. J. Nud Med. (1998) 39:1S.
  • VOSE JM, WAHL RL, SALEH M et al.: Multicenter Phase II study of iodine-131 tositumomab for chemotherapy-relapsed/ refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. Clin. Oncol (2000) 18:1316–1323.
  • •First multi-centre study, demonstrates reproducibility of dosimetric methodology.
  • KAMINSKI MS, ZELENETZ AD, PRESS OW et al: Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J. Clin. Oncol (2001) 19:3918–3928.
  • ••Pivotal study using patient as own control.Demonstrates that many patients have a longer duration of remission following tositumomab and 1131 tositumomab than from their previous chemotherapeutic regimen.
  • KAMINSKI M, ZELENETZ A, PRESS OW et al.: Tositumomab and iodine 1131 tositumomab (the BEXXAR therapeutic regimen) produced ongoing, durable remissions of more than 4 years in 9 patients with non-Hodgkin's lymphoma (NHL) in a pivotal study of patients refractory to their last chemotherapy. Blood (2004) 104:720a (abstract).
  • DAVIES AJ, ROHATINER AZ, HOWELL S et al: Tositumomab and iodine 1131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol (2004) 22:1469–1479.
  • LEONARD J, FRENETT G, DILLMAN RO, GREGORY SA: Interim safety and efficacy results of Bexxari'm in a large multicenter expanded access study. Blood (2001) 98:133a (abstract).
  • ARMITAGE JO, LEONARD J, GREGORY SA et al.: The effectiveness of tositumomab and iodine I 131 tositumomab in relapsed/refractory follicular grade 1/2 and small lymphocytic non-Hodgkin's lymphoma (NHL). Proc. Am. Soc. Clin. Oncol. (2004) 23:573 (abstract).
  • HORNING SJ, YOUNES A. JAIN V et al.: Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J. Clin. Oncol (2004) 23(4):712–719.
  • •Recent analysis of rituicimab-refractory patients.
  • COLEMAN M, KAMINSKI M, KNOX SJ, ZELENETZ AD, VOSE JM: The BEXXAR therapeutic regimen (tositumomab and iodine 1131 tositumomab) produced durable complete remissions in heavily pretreated patients with non-Hodgkins lymphoma (NHL), rituximab-relapseci/refractory disease, and rituximab-naive disease. Blood (2003) 102:29a (abstract).
  • LEONARD J, ZELENETZ A, VOSE JM, KAMINSKI M: Impact of course of therapy on response rate and duration with the Bexxar therapeutic regimen (tositumomab and iodine 1131 tositumomab) and with chemotherapy. Blood (2004) 104:41a (abstract).
  • ARMITAGE JO, DICK FR, CORDER MP: Diffuse histiocytic lymphoma after histologic conversion: a poor prognostic variant. Cancer Treat. Rep. (1981) 65:413–418.
  • ZELENETZ AD, SALEH M, VOSE JM, YOUNES A. KAMINSKI M: Patients with transformed low grade lymphoma attain durable responses following outpatient radioimmunotherapy with tositumomab and iodine 1131 tositumomab [Bexxar®]. Blood (2002) 100:357a (abstract).
  • KAMINSKI MS, TUCK M, ESTES J et al.: 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl. J. Med. (2005) 352(5):441–449.
  • BENNETT JM, KAMINSKI M, KNOX SJ et al.: Assessment of treatment-related myelodysplastic syndromes (tMDS) and acute myeloid leukemia (tAML) in patients with low-grade non-Hodgkins lymphoma (LG-NHL) treated with tositumomab and iodine-131 tositumomab (the BEXXAR therapeutic regimen). Blood (2003) 102:30a (abstract).
  • KAMINSKI M, KNOX SJ, RADFORD JA, GREGORY SA, LEONARD J: Re-treatment with tositumomab and iodine 1131 tositumomab (the BEXXAR therapeutic regimen) in patients with non-Hodgkins lymphoma (NHL) with a previous response to the BEXXAR therapeutic regimen. Blood (2003) 102:407a (abstract).
  • CZUCZMAN MS, GRILLO-LOPEZ AJ, WHITE CA et al.: of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J. Clin. Oncol. (1999) 17:268–276.
  • LEONARD J, COLEMAN M, KOSTAKOGLU Let al.: Durable remissions from fluciarabine followed by the iodine I-131 tositumomab Bexxar therapeutic regimen for patients with previously untreated follicular non-Hodgkin's lymphoma (NHL). Proc. Am. Soc. Clin. Oncol. (2004) 23:560 (abstract).
  • LINK B, KAMINSKI M, COLEMAN M, LEONARD J: Phase II study of CVP followed by tositumomab and iodine 1131 tositumomab (Bexxar therapeutic regimen) in patients with untreated follicular non-Hodgkin's lymphoma (NHL). Proc. Am. Soc. Clin. Oncol. (2004) 23:560 (abstract).
  • ZELENETZ AD, DONNELLY G, HALAAS J et al.: Initial treatment of mantle cell lymphoma with sequential radioimmunotherapy with tositumoamb/ iodine 1131 I-tositumoamb followed by CHOP chemotherapy results in a high complete remission rate. Blood (2003) 102:406a (abstract).
  • PRESS OW, EARY JF, APPELBAUM FR et al.: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl. J. Med. (1993) 329:1219–1224.
  • PRESS OW, EARY JF, APPELBAUM FR et al: Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet (1995) 346:336–340.
  • GOPAL AK, GOOLEY TA, MALONEY DG et al.: High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stern cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood (2003) 102:2351–2357.
  • PRESS OW, EARY JF, GOOLEY T et al.: A Phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stern cell transplantation for relapsed B-cell lymphomas. Blood (2000) 96:2934–2942.
  • VOSE JM, BIERMAN PJ, ENKE C et al.:Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stern-cell transplantation for relapsed non-Hodgkin's lymphoma. J. Clin. Oncol (2004) 23(3):461–467.
  • GLAXOSMITHKLINE: BEXXAR® Prescribing Information (2005).
  • GREGORY SA, ZELENETZ AD, KNOX SJ, VOSE JM, MAGNUSON, KAMINSKI MS: BexxarTm is an effective and well tolerated therapy in elderly patients with non-Hodgkin's lymphoma (NHL). Proc. Am. Soc. Clin. Oncol. (2001) 20:285a (abstract).
  • ARMITAGE JO, CARBONE PP, CONNORS JM, LEVINE A, BENNETT JM, KROLL S: Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J. Clin. Oncol. (2003) 21:897–906.
  • GREGORY SA, LEONARD J, KNOX SJ, ZELENETZ AD, ARMITAGE JO, KAMINSKI M: The iodine 1–131 tositumomab therapeutic regimen: summary of safety in 995 patients with relapsed/refractory low grade (LG) and transformed LG non-Hodgkin's lymphoma (NHL). Proc. Am. Soc. Clin. Oncol (2004) 23:613 (abstract).
  • KAMINSKI MS, TUCK M, FANG Y, COLCHER D, VALENTE NK, NIEDER M: Development of HAMA after BexxarTm does not preclude treatment with rituximab. Blood (2000) 96:734a (abstract).
  • VALENTE NK, KAMINSKI M, KNOX SJ et al.: Subsequent therapy can be administered following treatment with iodine 131 anti-B1 antibody in patients with non-Hodgkin's lymphoma. Ann. Oncol (1999) 10:33 (abstract).
  • RATANATHARATHORN V UBERTI JP, AYASH L, ESTES J, SILVERS, KAMINSKI MS: Haematopoietic stem cell transplantation in lymphoma patients receiving prior therapy with tositumomab and iodine P31 tositumomab (BexxarTm). Blood (2001) 98:200a (abstract).
  • KAMINSKI MS, BAHM V ESTES J, RATANATHARATHORN V: Tolerance of treatment subsequent to frontline BexxarTm (tositumomab and I 131 tositumomab) in patients with follicular lymphoma. Blood (2001) 98:603a (abstract).
  • CHESON BD: Some like it hot! J. Clin. Oncol (2001) 19:3908–3911.
  • DILLMAN RO: Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J. Clin. Oncol (2002) 20:3545–3557.
  • CHESON BD: Radioimmunotherapy of non-Hodgkin lymphomas. Blood (2003) 101:391–398.
  • •Comprehensive review of radioimmunotherapy of non-Hodgkin's lymphomas.
  • CORIXA CORPORARTION: Corbca announces sale and transfer of BEXXAR development and marketing rights to GlaxoSmithKline. (2004). Press Release.
  • SCHOUTEN HC, QIAN W, KVALOY S et al.: High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J. Clin. Oncol (2003) 21:3918–3927.
  • KHOURI IF, SALIBA RM, GIRALT SA et al.: Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood (2001) 98:3595–3599.
  • WITZIG TE, WHITE CA, WISEMAN GA et al.: Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J. Clin. Oncol (1999) 17:3793–3803.
  • WITZIG TE, FLINN IW, GORDON LI et al.: Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J. Clin. Oncol (2002) 20:3262–3269.
  • -WISEMAN GA, GORDON LI, MULTANI PS et al.: Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a Phase II multicenter trial. Blood (2002) 99:4336–4342.
  • WITZIG TE, GORDON LI, CABANILLAS F et al.: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol (2002) 20:2453–2463.
  • VOSE JM, LINK BK, GROSSBARD ML et al.: Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Clin. Oncol. (2001) 19:389–397.

Websites

  • http://www.fda.gov/ohrms/dockets/ac/02/ briefing/3916b1.htm Corixa Corp.: Oncology Drugs Advisory Committee Briefing Document. Iodine 1131 tositumomab (2002).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.